Lopinavir-Ritonavir Treatment for COVID-19 Infection in Intensive Care Unit: Risk of Bradycardia.
作者信息
Beyls Christophe, Martin Nicolas, Hermida Alexis, Abou-Arab Osama, Mahjoub Yazine
机构信息
Department of Anesthesiology and Critical Care Medicine (C.B., O.A.-A., Y.M.), Amiens University Hospital, France.
Department of Rythmology (N.M., A.H.), Amiens University Hospital, France.
出版信息
Circ Arrhythm Electrophysiol. 2020 Aug;13(8):e008798. doi: 10.1161/CIRCEP.120.008798. Epub 2020 Jul 9.
Abstract
摘要
相似文献
1
Lopinavir-Ritonavir Treatment for COVID-19 Infection in Intensive Care Unit: Risk of Bradycardia.洛匹那韦-利托那韦用于重症监护病房中新型冠状病毒肺炎感染的治疗：心动过缓风险
Circ Arrhythm Electrophysiol. 2020 Aug;13(8):e008798. doi: 10.1161/CIRCEP.120.008798. Epub 2020 Jul 9.
2
Caution With the Use of Lopinavir/Ritonavir in Severely Ill Patients for the Treatment of SARS-CoV-2: A Report of Severe Jaundice.严重疾病患者使用洛匹那韦/利托那韦治疗 SARS-CoV-2 时需谨慎：严重黄疸报告。
Am J Gastroenterol. 2020 Oct;115(10):1716-1718. doi: 10.14309/ajg.0000000000000828.
3
Ritonavir- and lopinavir-induced eryptosis in a SARS-CoV-2-infected patient.利托那韦和洛匹那韦在一名感染新型冠状病毒肺炎患者中诱导红细胞凋亡。
Blood. 2020 Aug 13;136(7):915. doi: 10.1182/blood.2020006228.
4
BET 1: Lopinavir-ritonavir and COVID-19.赌注1：洛匹那韦-利托那韦与2019冠状病毒病
Emerg Med J. 2020 Jul;37(7):450-451. doi: 10.1136/emermed-2020-210221.2.
5
Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations.SARS-CoV-2 全身炎症反应对洛匹那韦和羟氯喹血浆浓度的影响。
Antimicrob Agents Chemother. 2020 Aug 20;64(9). doi: 10.1128/AAC.01177-20.
6
Predictive factors for cardiac conduction abnormalities with hydroxychloroquine-containing combinations for COVID-19.羟氯喹联合治疗 COVID-19 导致心脏传导异常的预测因素。
Int J Antimicrob Agents. 2020 Oct;56(4):106142. doi: 10.1016/j.ijantimicag.2020.106142. Epub 2020 Aug 24.
7
Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.干扰素 β1a 对比干扰素 β1b 和常规治疗方案治疗中重度 COVID-19 成人患者的效果：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 3;21(1):473. doi: 10.1186/s13063-020-04382-3.
8
Direct oral anticoagulant plasma levels' striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: The Cremona experience.严重 COVID-19 呼吸综合征患者接受抗病毒药物治疗后直接口服抗凝剂血浆水平显著升高：克雷莫纳经验。
J Thromb Haemost. 2020 Jun;18(6):1320-1323. doi: 10.1111/jth.14871. Epub 2020 May 6.
9
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.洛匹那韦-利托那韦治疗成人重症 COVID-19 患者的临床试验。
N Engl J Med. 2020 May 7;382(19):1787-1799. doi: 10.1056/NEJMoa2001282. Epub 2020 Mar 18.
10
Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial.评价法维拉韦和干扰素与洛匹那韦/利托那韦和干扰素在 COVID-19 中度患者中的疗效和安全性：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Oct 27;21(1):886. doi: 10.1186/s13063-020-04747-8.
引用本文的文献
1
Examining efficacy and safety of ethyl acetate extract from as complementary therapy in COVID-19: A randomized, multicenter, controlled clinical trial.考察[具体植物名称]乙酸乙酯提取物作为COVID-19辅助疗法的疗效和安全性：一项随机、多中心、对照临床试验。 （注：原文中“as complementary therapy in COVID-19”前缺少具体植物名称，翻译时添加了[具体植物名称]以保证句子完整通顺）
Avicenna J Phytomed. 2024 Nov-Dec;14(6):699-710. doi: 10.22038/AJP.2024.24523.
2
Cardiac Arrhythmias and Autonomic Dysfunction Associated With COVID-19: A Scientific Statement From the American Heart Association.与 COVID-19 相关的心律失常和自主神经功能障碍：美国心脏协会的科学声明。
Circulation. 2024 Nov 19;150(21):e449-e465. doi: 10.1161/CIR.0000000000001290. Epub 2024 Oct 14.
3
Preclinical and Clinical Investigations of Potential Drugs and Vaccines for COVID-19 Therapy: A Comprehensive Review With Recent Update.COVID-19治疗潜在药物和疫苗的临床前与临床研究：近期更新的综合综述
Clin Pathol. 2024 Jul 26;17:2632010X241263054. doi: 10.1177/2632010X241263054. eCollection 2024 Jan-Dec.
4
Global Perspective on COVID-19 Therapies, Cardiovascular Outcomes, and Implications for Long COVID: A State-of-the-Art Review.关于新冠病毒治疗、心血管结局及对新冠长期症状影响的全球视角：最新综述
J Community Hosp Intern Med Perspect. 2024 Mar 4;14(2):58-66. doi: 10.55729/2000-9666.1308. eCollection 2024.
5
Importance of Magnesium Status in COVID-19.镁状态在2019冠状病毒病中的重要性。
Biology (Basel). 2023 May 18;12(5):735. doi: 10.3390/biology12050735.
6
Possible nirmatrelvir/ritonavir-induced bradycardia in a patient with asymptomatic COVID-19.无症状新冠病毒感染者中可能由奈玛特韦/利托那韦引起的心动过缓。
SAGE Open Med Case Rep. 2023 Apr 20;11:2050313X231168304. doi: 10.1177/2050313X231168304. eCollection 2023.
7
Long COVID-19 and the Heart: Is Cardiac Mitochondria the Missing Link?长新冠和心脏：心脏线粒体是缺失的一环吗？
Antioxid Redox Signal. 2023 Mar;38(7-9):599-618. doi: 10.1089/ars.2022.0126. Epub 2022 Dec 28.
8
Transcriptional Effects of Candidate COVID-19 Treatments on Cardiac Myocytes.新型冠状病毒肺炎候选治疗药物对心肌细胞的转录影响
Front Cardiovasc Med. 2022 May 24;9:844441. doi: 10.3389/fcvm.2022.844441. eCollection 2022.
9
Molecular Insights of SARS-CoV-2 Antivirals Administration: A Balance between Safety Profiles and Impact on Cardiovascular Phenotypes.新型冠状病毒2型抗病毒药物给药的分子见解：安全性与对心血管表型影响之间的平衡
Biomedicines. 2022 Feb 14;10(2):437. doi: 10.3390/biomedicines10020437.
10
Mass spectrometry applied to diagnosis, prognosis, and therapeutic targets identification for the novel coronavirus SARS-CoV-2: A review.质谱分析在新型冠状病毒 SARS-CoV-2 的诊断、预后和治疗靶点鉴定中的应用：综述。
Anal Chim Acta. 2022 Feb 22;1195:339385. doi: 10.1016/j.aca.2021.339385. Epub 2021 Dec 20.
本文引用的文献
1
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.洛匹那韦-利托那韦治疗成人重症 COVID-19 患者的临床试验。
N Engl J Med. 2020 May 7;382(19):1787-1799. doi: 10.1056/NEJMoa2001282. Epub 2020 Mar 18.
2
CYP3A4-mediated lopinavir bioactivation and its inhibition by ritonavir.CYP3A4 介导的洛匹那韦生物活化及其被利托那韦抑制。
Drug Metab Dispos. 2012 Jan;40(1):18-24. doi: 10.1124/dmd.111.041400. Epub 2011 Sep 27.
3
Extreme bradycardia due to multiple drug-drug interactions in a patient with HIV post-exposure prophylaxis containing lopinavir-ritonavir.一名接受含洛匹那韦-利托那韦的HIV暴露后预防治疗的患者，因多种药物相互作用导致严重心动过缓。
Br J Clin Pharmacol. 2011 Apr;71(4):621-3. doi: 10.1111/j.1365-2125.2010.03849.x.
4
Bradycardia-tachycardia syndrome induced by lopinavir-ritonavir in a patient with AIDS.洛匹那韦-利托那韦诱发艾滋病患者的心动过缓-心动过速综合征。
AIDS. 2005 Sep 23;19(14):1547-8. doi: 10.1097/01.aids.0000183942.05849.1b.
5
Influence of the pro-inflammatory cytokines on P-glycoprotein expression and functionality.促炎细胞因子对P-糖蛋白表达及功能的影响。
J Pharm Pharm Sci. 2004 Nov 17;7(3):359-71.
6
Serious bradyarrhythmia that was possibly induced by lopinavir-ritonavir in 2 patients with acquired immunodeficiency syndrome.2例获得性免疫缺陷综合征患者可能由洛匹那韦-利托那韦诱发的严重缓慢性心律失常。
Clin Infect Dis. 2002 Aug 15;35(4):488-90. doi: 10.1086/341975. Epub 2002 Jul 17.
Zotero 插件